NCT01586364View on ClinicalTrials.gov

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

PHASE3CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

May 8, 2006

Primary Completion Date

November 21, 2008

Study Completion Date

December 22, 2008

Conditions
AtrophyVaginal Diseases
Interventions
DRUG

Ospemifene 60Mg Oral Tablet

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
collaborator

QuatRx Pharmaceuticals

INDUSTRY

lead

Shionogi

INDUSTRY

NCT01586364 - Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus | Biotech Hunter | Biotech Hunter